{"success":true,"data":{"pressRelease":{"id":"167522","rtpr_id":"nPn9ySq48a-20261013","ticker":"ICCM","exchange":"NASDAQ","all_tickers":["ICCM"],"title":"IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026","author":"PR Newswire","published_at":"2026-10-13T12:05:02.535Z","article_body":"IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026\nPR Newswire\n\nCAESAREA, Israel, October 13, 2026\n\nScientific presentations, research posters and clinical workshops featured\nProSense(® )breast cancer cryoablation and highlighted strong physician\nengagement across Europe\n\nCAESAREA, Israel, October 13, 2026 /PRNewswire/ -- IceCure Medical Ltd.\n(http://www.icecure-medical.com/)  (Nasdaq: ICCM) (\"IceCure,\" \"IceCure\nMedical\" or the \"Company\"), developer of minimally-invasive cryoablation\ntechnology that destroys tumors by freezing as an option to surgical tumor\nremoval, announced today that ProSense(® )breast cancer cryoablation was\nfeatured in multiple scientific presentations, research posters and physician\nworkshops at the European Society of Breast Imaging (\"EUSOBI\") Annual\nScientific Meeting 2026, held in Maastricht, the Netherlands. Featured\npresentations included 12-month clinical data reporting objective response\nrates of 97.5% among 40 patients treated with cryoablation plus endocrine\ntherapy and 91.7% among 24 patients treated with cryoablation alone.\n\nProSense(® )was featured during two key scientific sessions at EUSOBI,\nreflecting clinical interest in breast cancer cryoablation in Europe. Dr.\nLucía Graña-López (Lugo, Spain) presented the clinical potential of\ncryoablation during her presentation \"Beyond Biopsy: Image-Guided Therapy in\nPractice\" during the session \"From Target to Treatment: Breast Interventions.\"\nDr. Francesca Pugliese (Florence, Italy) shared her findings from \"Local\nTumor Control in Elderly Breast Cancer Patients Ineligible for Surgery:\nCryoablation Alone or Combined with Hormonal Therapy\n(https://eusobi2026.smart-abstract.com/eposter/#/posters/84/presentation/topic/4)\n\" during the session on \"Advances in Image-Guided Breast Intervention and\nMinimally Invasive Therapy.\"\n\nThe Company also hosted two well-attended clinical workshops, led by Dr.\nLucía Graña-López (Lugo, Spain) and Dr. Federica Di Naro (Florence, Italy):\n\"From Freeze to Future: Cryoablation as a New Frontier in De-Escalated Breast\nCancer Care\" and \"Reading the Freeze: Practical Imaging Interpretation After\nBreast Cancer Cryoablation\". Each workshop attracted nearly 70 participants.\n\nTwo scientific posters by ProSense(® )users were presented: \"From Initial\nExperience to One-Year Outcomes: Single-Center Efficacy and Safety of\nPercutaneous Cryoablation for Breast Lesions in Romania\"\n(https://eusobi2026.smart-abstract.com/eposter/#/posters/54/presentation/topic/2)\n by Dr. Georgiana-Cristiana Camen (Romania) and \"When Enhancement Disappears:\nThe Role of Negative CEM (Contrast Enhancement Mammography) in Predicting\nHistological Response After Breast Cryoablation\n(https://eusobi2026.smart-abstract.com/eposter/#/posters/74/presentation/topic/2)\n\" by Dr. Francesca Pugliese (Florence, Italy).\n\nEUSOBI is a leading European organization dedicated to breast imaging and\neducation, bringing together breast radiologists and other specialists from\nacross Europe and internationally. The Annual Scientific Meeting provides a\nplatform for the exchange of clinical knowledge, research and advances in\nbreast imaging and treatment.\n\n\"We are thrilled by the tremendous enthusiasm and engagement ProSense(®\n)generated throughout EUSOBI,\" said Eyal Shamir, Chief Executive Officer of\nIceCure Medical. \"From live demonstrations and two key scientific sessions to\ntwo workshops attended by nearly 70 participants each, the response was\noutstanding. The inclusion of ProSense(® )in scientific posters and the\npresentation of encouraging 12-month clinical results further demonstrate the\ngrowing momentum behind breast cancer cryoablation and the expanding role of\nProSense(® )in advancing minimally invasive care across Europe.\"\n\nAbout IceCure Medical\n\nIceCure Medical (Nasdaq: ICCM) develops and markets advanced\nliquid-nitrogen-based cryoablation therapy systems for the destruction of\ntumors (benign and cancerous) by freezing, as a safe and effective minimally\ninvasive option to surgical tumor removal, with the primary focus areas being\nbreast, kidney, bone and lung cancer. The Company's flagship ProSense(®\n)system is marketed and sold worldwide for the indications cleared and\napproved to date including in the U.S., Europe, and Asia.\n\nProSense(® )cryoablation became the first-and-only medical device cleared by\nthe FDA for the local treatment of breast cancer in patients aged 70 years and\nolder with biologically low-risk tumors ≤1.5 cm in size who are treated with\nadjuvant endocrine therapy, including patients who are not eligible for\nsurgery.\n\nInvestor Relations:\n\nMeir Peleg, CFO\n\ninvestors@icecure-medical.com (mailto:investors@icecure-medical.com)\n\n+1-888-902-5716\n\nForward Looking Statements\n\nThis press release contains \"forward-looking statements\" within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended, that are intended to be covered\nby the \"safe harbor\" created by those sections. Forward-looking statements,\nwhich are based on certain assumptions and describe our future plans,\nstrategies and expectations, can generally be identified by the use of\nforward-looking terms such as \"believe,\" \"expect,\" \"may,\" \"should,\" \"could,\"\n\"seek,\" \"intend,\" \"plan,\" \"goal,\" \"estimate,\" \"anticipate\" or other comparable\nterms. For example, the Company is using forward-looking statements when it\ndiscusses: the potential for increased physician interest in, adoption of, and\nuse of ProSense(® )and breast cancer cryoablation, including in Europe; the\npotential of expansion of ProSense(®)'s role in minimally invasive breast\ncancer care; and the potential for broader commercial adoption of\nProSense(®). Important factors that could cause actual results, developments\nand business decisions to differ materially from those anticipated in these\nforward-looking statements include, among others: the Company's planned level\nof revenues and capital expenditures; the Company's available cash and its\nability to obtain additional funding; the Company's ability to market and sell\nits products; legal and regulatory developments in the United States and other\ncountries; the Company's ability to maintain its relationships with suppliers,\ndistributors and other partners; the Company's ability to maintain or protect\nthe validity of its patents and other intellectual property; the Company's\nability to expose and educate medical professionals about its products;\npolitical, economic and military instability in the Middle East, specifically\nin Israel; as well as those factors set forth in the Risk Factors section of\nthe Company's Annual Report on Form 20-F for the year ended December 31, 2025\nfiled with the SEC on March 17, 2026, and other documents filed with or\nfurnished to the SEC which are available on the SEC's website, www.sec.gov\n(http://www.sec.gov/) . The Company undertakes no obligation to update these\nstatements for revisions or changes after the date of this release, except as\nrequired by law.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/icecure-highlights-clinical-data-and-strong-physician-engagement-for-prosense-breast-cancer-cryoablation-at-eusobi-2026-302906818.html\n(https://www.prnewswire.com/news-releases/icecure-highlights-clinical-data-and-strong-physician-engagement-for-prosense-breast-cancer-cryoablation-at-eusobi-2026-302906818.html)\n\nSOURCE IceCure Medical\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1519561/IceCure-Medical-Logo.jpg?id=OA3015216\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn9ySq48a-20261013","title":"IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026","author":"PR Newswire","ticker":"ICCM","created":"2026-10-13T12:05:02.535Z","tickers":["ICCM"],"exchange":"NASDAQ","article_body":"IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026\nPR Newswire\n\nCAESAREA, Israel, October 13, 2026\n\nScientific presentations, research posters and clinical workshops featured\nProSense(® )breast cancer cryoablation and highlighted strong physician\nengagement across Europe\n\nCAESAREA, Israel, October 13, 2026 /PRNewswire/ -- IceCure Medical Ltd.\n(http://www.icecure-medical.com/)  (Nasdaq: ICCM) (\"IceCure,\" \"IceCure\nMedical\" or the \"Company\"), developer of minimally-invasive cryoablation\ntechnology that destroys tumors by freezing as an option to surgical tumor\nremoval, announced today that ProSense(® )breast cancer cryoablation was\nfeatured in multiple scientific presentations, research posters and physician\nworkshops at the European Society of Breast Imaging (\"EUSOBI\") Annual\nScientific Meeting 2026, held in Maastricht, the Netherlands. Featured\npresentations included 12-month clinical data reporting objective response\nrates of 97.5% among 40 patients treated with cryoablation plus endocrine\ntherapy and 91.7% among 24 patients treated with cryoablation alone.\n\nProSense(® )was featured during two key scientific sessions at EUSOBI,\nreflecting clinical interest in breast cancer cryoablation in Europe. Dr.\nLucía Graña-López (Lugo, Spain) presented the clinical potential of\ncryoablation during her presentation \"Beyond Biopsy: Image-Guided Therapy in\nPractice\" during the session \"From Target to Treatment: Breast Interventions.\"\nDr. Francesca Pugliese (Florence, Italy) shared her findings from \"Local\nTumor Control in Elderly Breast Cancer Patients Ineligible for Surgery:\nCryoablation Alone or Combined with Hormonal Therapy\n(https://eusobi2026.smart-abstract.com/eposter/#/posters/84/presentation/topic/4)\n\" during the session on \"Advances in Image-Guided Breast Intervention and\nMinimally Invasive Therapy.\"\n\nThe Company also hosted two well-attended clinical workshops, led by Dr.\nLucía Graña-López (Lugo, Spain) and Dr. Federica Di Naro (Florence, Italy):\n\"From Freeze to Future: Cryoablation as a New Frontier in De-Escalated Breast\nCancer Care\" and \"Reading the Freeze: Practical Imaging Interpretation After\nBreast Cancer Cryoablation\". Each workshop attracted nearly 70 participants.\n\nTwo scientific posters by ProSense(® )users were presented: \"From Initial\nExperience to One-Year Outcomes: Single-Center Efficacy and Safety of\nPercutaneous Cryoablation for Breast Lesions in Romania\"\n(https://eusobi2026.smart-abstract.com/eposter/#/posters/54/presentation/topic/2)\n by Dr. Georgiana-Cristiana Camen (Romania) and \"When Enhancement Disappears:\nThe Role of Negative CEM (Contrast Enhancement Mammography) in Predicting\nHistological Response After Breast Cryoablation\n(https://eusobi2026.smart-abstract.com/eposter/#/posters/74/presentation/topic/2)\n\" by Dr. Francesca Pugliese (Florence, Italy).\n\nEUSOBI is a leading European organization dedicated to breast imaging and\neducation, bringing together breast radiologists and other specialists from\nacross Europe and internationally. The Annual Scientific Meeting provides a\nplatform for the exchange of clinical knowledge, research and advances in\nbreast imaging and treatment.\n\n\"We are thrilled by the tremendous enthusiasm and engagement ProSense(®\n)generated throughout EUSOBI,\" said Eyal Shamir, Chief Executive Officer of\nIceCure Medical. \"From live demonstrations and two key scientific sessions to\ntwo workshops attended by nearly 70 participants each, the response was\noutstanding. The inclusion of ProSense(® )in scientific posters and the\npresentation of encouraging 12-month clinical results further demonstrate the\ngrowing momentum behind breast cancer cryoablation and the expanding role of\nProSense(® )in advancing minimally invasive care across Europe.\"\n\nAbout IceCure Medical\n\nIceCure Medical (Nasdaq: ICCM) develops and markets advanced\nliquid-nitrogen-based cryoablation therapy systems for the destruction of\ntumors (benign and cancerous) by freezing, as a safe and effective minimally\ninvasive option to surgical tumor removal, with the primary focus areas being\nbreast, kidney, bone and lung cancer. The Company's flagship ProSense(®\n)system is marketed and sold worldwide for the indications cleared and\napproved to date including in the U.S., Europe, and Asia.\n\nProSense(® )cryoablation became the first-and-only medical device cleared by\nthe FDA for the local treatment of breast cancer in patients aged 70 years and\nolder with biologically low-risk tumors ≤1.5 cm in size who are treated with\nadjuvant endocrine therapy, including patients who are not eligible for\nsurgery.\n\nInvestor Relations:\n\nMeir Peleg, CFO\n\ninvestors@icecure-medical.com (mailto:investors@icecure-medical.com)\n\n+1-888-902-5716\n\nForward Looking Statements\n\nThis press release contains \"forward-looking statements\" within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended, that are intended to be covered\nby the \"safe harbor\" created by those sections. Forward-looking statements,\nwhich are based on certain assumptions and describe our future plans,\nstrategies and expectations, can generally be identified by the use of\nforward-looking terms such as \"believe,\" \"expect,\" \"may,\" \"should,\" \"could,\"\n\"seek,\" \"intend,\" \"plan,\" \"goal,\" \"estimate,\" \"anticipate\" or other comparable\nterms. For example, the Company is using forward-looking statements when it\ndiscusses: the potential for increased physician interest in, adoption of, and\nuse of ProSense(® )and breast cancer cryoablation, including in Europe; the\npotential of expansion of ProSense(®)'s role in minimally invasive breast\ncancer care; and the potential for broader commercial adoption of\nProSense(®). Important factors that could cause actual results, developments\nand business decisions to differ materially from those anticipated in these\nforward-looking statements include, among others: the Company's planned level\nof revenues and capital expenditures; the Company's available cash and its\nability to obtain additional funding; the Company's ability to market and sell\nits products; legal and regulatory developments in the United States and other\ncountries; the Company's ability to maintain its relationships with suppliers,\ndistributors and other partners; the Company's ability to maintain or protect\nthe validity of its patents and other intellectual property; the Company's\nability to expose and educate medical professionals about its products;\npolitical, economic and military instability in the Middle East, specifically\nin Israel; as well as those factors set forth in the Risk Factors section of\nthe Company's Annual Report on Form 20-F for the year ended December 31, 2025\nfiled with the SEC on March 17, 2026, and other documents filed with or\nfurnished to the SEC which are available on the SEC's website, www.sec.gov\n(http://www.sec.gov/) . The Company undertakes no obligation to update these\nstatements for revisions or changes after the date of this release, except as\nrequired by law.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/icecure-highlights-clinical-data-and-strong-physician-engagement-for-prosense-breast-cancer-cryoablation-at-eusobi-2026-302906818.html\n(https://www.prnewswire.com/news-releases/icecure-highlights-clinical-data-and-strong-physician-engagement-for-prosense-breast-cancer-cryoablation-at-eusobi-2026-302906818.html)\n\nSOURCE IceCure Medical\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1519561/IceCure-Medical-Logo.jpg?id=OA3015216\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-13T12:05:02.633689936Z","server_sent_at_ms":1791893102633},"received_at":"2026-10-13T12:05:02.685Z","source_url":"https://www.prnewswire.com/news-releases/icecure-highlights-clinical-data-and-strong-physician-engagement-for-prosense-breast-cancer-cryoablation-at-eusobi-2026-302906818.html"},"analysis":{"id":"155816","press_release_id":"167522","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"IceCure Medical's ProSense breast cancer cryoablation was featured in scientific sessions, posters and workshops at the EUSOBI 2026 Annual Scientific Meeting in Maastricht.\n\nFeatured 12-month data showed objective response rates of 97.5% in 40 patients treated with cryoablation plus endocrine therapy and 91.7% in 24 patients treated with cryoablation alone.\n\nTwo company-hosted workshops each drew nearly 70 participants, which management cited as evidence of growing European physician adoption of minimally invasive cryoablation.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Strong European physician engagement and encouraging 12-month response data build the adoption case for ProSense, though it is conference-level visibility rather than a pivotal milestone."},"keyFigures":{"drugName":"ProSense","customDimensions":{"workshop_participants":"nearly 70 per workshop","patients_cryoablation_alone":24,"objective_response_rate_cryoablation_alone":"91.7%","patients_cryoablation_plus_endocrine_therapy":40,"objective_response_rate_cryoablation_plus_endocrine_therapy":"97.5%"}},"quotedText":"We are thrilled by the tremendous enthusiasm and engagement ProSense generated throughout EUSOBI","namedEntities":{"people":[{"name":"Eyal Shamir","role":"CEO"},{"name":"Dr. Lucía Graña-López","role":"presenting physician"},{"name":"Dr. Francesca Pugliese","role":"presenting physician"},{"name":"Dr. Federica Di Naro","role":"workshop leader"},{"name":"Dr. Georgiana-Cristiana Camen","role":"poster author"},{"name":"Meir Peleg","role":"CFO"}],"products":["ProSense"],"companies":[{"name":"IceCure Medical Ltd.","ticker":"ICCM","relationship":"filer"},{"name":"European Society of Breast Imaging (EUSOBI)","relationship":"conference organizer"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Positive 12-month response-rate data (97.5% with cryoablation plus endocrine therapy; 91.7% cryoablation alone) and strong European physician engagement at EUSOBI, but this is conference visibility rather than a pivotal-trial readout or regulatory event."},"tickerRelevance":{"others":[],"primary":"ICCM"},"globalImportance":22,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"conference data showcase","clinicalSignal":"positive but non-pivotal","householdBrandBoost":0,"retailFavoriteBoost":0}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"IceCure Medical's ProSense breast cancer cryoablation was featured in scientific sessions, posters and workshops at the EUSOBI 2026 Annual Scientific Meeting in Maastricht.\n\nFeatured 12-month data showed objective response rates of 97.5% in 40 patients treated with cryoablation plus endocrine therapy and 91.7% in 24 patients treated with cryoablation alone.\n\nTwo company-hosted workshops each drew nearly 70 participants, which management cited as evidence of growing European physician adoption of minimally invasive cryoablation.","key_figures":{"drugName":"ProSense","customDimensions":{"workshop_participants":"nearly 70 per workshop","patients_cryoablation_alone":24,"objective_response_rate_cryoablation_alone":"91.7%","patients_cryoablation_plus_endocrine_therapy":40,"objective_response_rate_cryoablation_plus_endocrine_therapy":"97.5%"}},"named_entities":{"people":[{"name":"Eyal Shamir","role":"CEO"},{"name":"Dr. Lucía Graña-López","role":"presenting physician"},{"name":"Dr. Francesca Pugliese","role":"presenting physician"},{"name":"Dr. Federica Di Naro","role":"workshop leader"},{"name":"Dr. Georgiana-Cristiana Camen","role":"poster author"},{"name":"Meir Peleg","role":"CFO"}],"products":["ProSense"],"companies":[{"name":"IceCure Medical Ltd.","ticker":"ICCM","relationship":"filer"},{"name":"European Society of Breast Imaging (EUSOBI)","relationship":"conference organizer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-13T12:05:08.227Z","global_importance":22,"audience_relevance":25,"importance_components":{"tickerTier":"micro-cap","eventGravity":"conference data showcase","clinicalSignal":"positive but non-pivotal","householdBrandBoost":0,"retailFavoriteBoost":0}},"durationMs":5510,"modelName":"glm-5.3-flashx"}}